CA2283758C - Spinocerebellar ataxia type 8 and methods of detection - Google Patents
Spinocerebellar ataxia type 8 and methods of detection Download PDFInfo
- Publication number
- CA2283758C CA2283758C CA2283758A CA2283758A CA2283758C CA 2283758 C CA2283758 C CA 2283758C CA 2283758 A CA2283758 A CA 2283758A CA 2283758 A CA2283758 A CA 2283758A CA 2283758 C CA2283758 C CA 2283758C
- Authority
- CA
- Canada
- Prior art keywords
- seq
- nucleotides
- repeat region
- ctg
- repeat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 201000003629 Spinocerebellar ataxia type 8 Diseases 0.000 title claims abstract description 222
- 238000000034 method Methods 0.000 title claims description 88
- 238000001514 detection method Methods 0.000 title description 6
- 108091026890 Coding region Proteins 0.000 claims abstract description 101
- 230000000295 complement effect Effects 0.000 claims abstract description 77
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 50
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 49
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 49
- 210000000349 chromosome Anatomy 0.000 claims abstract description 16
- 239000002773 nucleotide Substances 0.000 claims description 194
- 125000003729 nucleotide group Chemical group 0.000 claims description 194
- 108020004414 DNA Proteins 0.000 claims description 188
- 239000013615 primer Substances 0.000 claims description 180
- 239000012634 fragment Substances 0.000 claims description 83
- 108091034117 Oligonucleotide Proteins 0.000 claims description 74
- 108700028369 Alleles Proteins 0.000 claims description 58
- 239000000523 sample Substances 0.000 claims description 56
- 206010003591 Ataxia Diseases 0.000 claims description 48
- 239000002299 complementary DNA Substances 0.000 claims description 45
- 102000053602 DNA Human genes 0.000 claims description 34
- 239000013598 vector Substances 0.000 claims description 22
- 208000024891 symptom Diseases 0.000 claims description 19
- 238000009396 hybridization Methods 0.000 claims description 13
- 108091008146 restriction endonucleases Proteins 0.000 claims description 11
- 108020004635 Complementary DNA Proteins 0.000 claims description 10
- 239000003155 DNA primer Substances 0.000 claims description 9
- 238000012163 sequencing technique Methods 0.000 claims description 8
- 238000010804 cDNA synthesis Methods 0.000 claims description 7
- 230000002194 synthesizing effect Effects 0.000 claims description 7
- 230000003297 denaturating effect Effects 0.000 claims description 2
- 238000002405 diagnostic procedure Methods 0.000 abstract description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 38
- 108020004999 messenger RNA Proteins 0.000 description 33
- 239000000047 product Substances 0.000 description 27
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 201000010099 disease Diseases 0.000 description 21
- 238000010367 cloning Methods 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 102000014461 Ataxins Human genes 0.000 description 12
- 108010078286 Ataxins Proteins 0.000 description 12
- 206010008025 Cerebellar ataxia Diseases 0.000 description 12
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 11
- 238000003745 diagnosis Methods 0.000 description 11
- 230000005540 biological transmission Effects 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 108700024394 Exon Proteins 0.000 description 9
- 102000007372 Ataxin-1 Human genes 0.000 description 8
- 108010032963 Ataxin-1 Proteins 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 238000010222 PCR analysis Methods 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 230000008774 maternal effect Effects 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 description 8
- 230000003321 amplification Effects 0.000 description 7
- 210000001638 cerebellum Anatomy 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 239000003298 DNA probe Substances 0.000 description 6
- 238000002944 PCR assay Methods 0.000 description 6
- 238000007857 nested PCR Methods 0.000 description 6
- 239000002987 primer (paints) Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 206010039509 Scab Diseases 0.000 description 5
- 108091081021 Sense strand Proteins 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000008775 paternal effect Effects 0.000 description 5
- 108010040003 polyglutamine Proteins 0.000 description 5
- 229920000155 polyglutamine Polymers 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108020005544 Antisense RNA Proteins 0.000 description 4
- 108020003215 DNA Probes Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 206010068871 Myotonic dystrophy Diseases 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 241001274197 Scatophagus argus Species 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 206010013887 Dysarthria Diseases 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 108020005067 RNA Splice Sites Proteins 0.000 description 3
- 108091036066 Three prime untranslated region Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000000869 mutational effect Effects 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100035087 Ectoderm-neural cortex protein 1 Human genes 0.000 description 2
- 108050003258 Ectoderm-neural cortex protein 1 Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000005622 Gait Ataxia Diseases 0.000 description 2
- 206010017577 Gait disturbance Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 108010040897 Microfilament Proteins Proteins 0.000 description 2
- 102000002151 Microfilament Proteins Human genes 0.000 description 2
- 208000008238 Muscle Spasticity Diseases 0.000 description 2
- 102100028762 Neuropilin-1 Human genes 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001977 ataxic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000001652 frontal lobe Anatomy 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 206010029864 nystagmus Diseases 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000004513 sizing Methods 0.000 description 2
- 230000001148 spastic effect Effects 0.000 description 2
- 208000018198 spasticity Diseases 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 2
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 206010003504 Aspiration Diseases 0.000 description 1
- 102000008836 BTB/POZ domains Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108700041998 Drosophila kel Proteins 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017585 Gait spastic Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 101000775732 Homo sapiens Androgen receptor Proteins 0.000 description 1
- 208000027747 Kennedy disease Diseases 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 description 1
- 102100022437 Myotonin-protein kinase Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 1
- 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102220531209 Uncharacterized protein KIAA2012_F27R_mutation Human genes 0.000 description 1
- 101710185494 Zinc finger protein Proteins 0.000 description 1
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- -1 glutamine amino acids Chemical class 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 201000003636 hereditary ataxia Diseases 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 210000001767 medulla oblongata Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000005015 neuronal process Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000004260 spinocerebellar tract Anatomy 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 210000004281 subthalamic nucleus Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/181,585 | 1998-10-28 | ||
| US09/181,585 US6524791B1 (en) | 1998-10-28 | 1998-10-28 | Spinocerebellar ataxia type 8 and methods of detection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2283758A1 CA2283758A1 (en) | 2000-04-28 |
| CA2283758C true CA2283758C (en) | 2011-05-10 |
Family
ID=22664902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2283758A Expired - Lifetime CA2283758C (en) | 1998-10-28 | 1999-09-27 | Spinocerebellar ataxia type 8 and methods of detection |
Country Status (3)
| Country | Link |
|---|---|
| US (5) | US6524791B1 (enExample) |
| JP (1) | JP4637982B2 (enExample) |
| CA (1) | CA2283758C (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6514755B1 (en) * | 1998-08-18 | 2003-02-04 | Regents Of The University Of Minnesota | SCA7 gene and methods of use |
| US6524791B1 (en) | 1998-10-28 | 2003-02-25 | Regents Of The University Of Minnesota | Spinocerebellar ataxia type 8 and methods of detection |
| KR20030013019A (ko) * | 2001-08-06 | 2003-02-14 | 주식회사 바이오메드랩 | 삼핵산 반복서열 증가질환용 진단키트 및 진단장치 |
| US8963713B2 (en) | 2005-03-16 | 2015-02-24 | Icontrol Networks, Inc. | Integrated security network with security alarm signaling system |
| JP5716217B2 (ja) * | 2009-12-15 | 2015-05-13 | 公益財団法人ヒューマンサイエンス振興財団 | 長鎖繰返し配列を含有する遺伝子又は遺伝子産物の選択又は優先的回収方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683194A (en) | 1984-05-29 | 1987-07-28 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5558988A (en) * | 1992-11-13 | 1996-09-24 | Thomas Jefferson University | Primers and methods for detecting mutations in the procollagen II gene that indicate a genetic predisposition for osteoarthritis |
| US5695933A (en) * | 1993-05-28 | 1997-12-09 | Massachusetts Institute Of Technology | Direct detection of expanded nucleotide repeats in the human genome |
| US5834183A (en) | 1993-06-29 | 1998-11-10 | Regents Of The University Of Minnesota | Gene sequence for spinocerebellar ataxia type 1 and method for diagnosis |
| US5741645A (en) | 1993-06-29 | 1998-04-21 | Regents Of The University Of Minnesota | Gene sequence for spinocerebellar ataxia type 1 and method for diagnosis |
| WO1997042314A1 (en) | 1996-05-08 | 1997-11-13 | Cedars-Sinai Medical Center | Nucleic acid encoding spinocerebellar ataxia-2 and products related thereto |
| US5807743A (en) * | 1996-12-03 | 1998-09-15 | Ribozyme Pharmaceuticals, Inc. | Interleukin-2 receptor gamma-chain ribozymes |
| US6280938B1 (en) | 1997-08-19 | 2001-08-28 | Regents Of The University Of Minnesota | SCA7 gene and method of use |
| US6183953B1 (en) * | 1997-09-15 | 2001-02-06 | Zymogenetics, Inc. | Chromosomal mutagenesis in Pichia methanolica |
| US6524791B1 (en) | 1998-10-28 | 2003-02-25 | Regents Of The University Of Minnesota | Spinocerebellar ataxia type 8 and methods of detection |
-
1998
- 1998-10-28 US US09/181,585 patent/US6524791B1/en not_active Expired - Lifetime
-
1999
- 1999-09-27 CA CA2283758A patent/CA2283758C/en not_active Expired - Lifetime
- 1999-10-28 JP JP30662899A patent/JP4637982B2/ja not_active Expired - Lifetime
-
2003
- 2003-02-24 US US10/373,667 patent/US7741458B2/en not_active Expired - Fee Related
-
2010
- 2010-06-21 US US12/819,749 patent/US8247173B2/en not_active Expired - Fee Related
-
2012
- 2012-08-20 US US13/589,266 patent/US8748096B2/en not_active Expired - Fee Related
-
2014
- 2014-04-28 US US14/263,064 patent/US9556488B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2000201677A (ja) | 2000-07-25 |
| US20030235841A1 (en) | 2003-12-25 |
| US6524791B1 (en) | 2003-02-25 |
| JP4637982B2 (ja) | 2011-02-23 |
| CA2283758A1 (en) | 2000-04-28 |
| US7741458B2 (en) | 2010-06-22 |
| US8247173B2 (en) | 2012-08-21 |
| US20140322711A1 (en) | 2014-10-30 |
| US9556488B2 (en) | 2017-01-31 |
| US20130029335A1 (en) | 2013-01-31 |
| US8748096B2 (en) | 2014-06-10 |
| US20100317015A1 (en) | 2010-12-16 |
| US20130230849A9 (en) | 2013-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kurth et al. | Association of a monoamine oxidase B allele with Parkinson's disease | |
| Campbell et al. | Genomic variation and gene conversion in spinal muscular atrophy: implications for disease process and clinical phenotype | |
| Bourdon et al. | A detailed analysis of the MECP2 gene: prevalence of recurrent mutations and gross DNA rearrangements in Rett syndrome patients | |
| IL229825A (en) | Materials and methods for identifying spinal cord atrophy carriers | |
| US11214834B2 (en) | Methods of detecting Charcot-Marie tooth disease type 2A | |
| US9556488B2 (en) | Spinocerebellar ataxia type 8 and methods of detection | |
| US8206911B2 (en) | Identification of the gene and mutation responsible for progressive rod-cone degeneration in dog and a method for testing same | |
| US7488576B2 (en) | Methods for diagnosis and treatment of psychiatric disorders | |
| US20030134272A1 (en) | Mutation analysis of the NF1 gene | |
| Patrono et al. | Missense and splice site mutations in SPG4 suggest loss-of-function in dominant spastic paraplegia | |
| EP2707497B1 (en) | Detecting the brachyspina mutation | |
| WO2000006769A2 (en) | Human ccr-2 gene polymorphisms | |
| CA2598281C (en) | Sptbn2 gene associated with spinocerebellar ataxia type 5 and methods of use | |
| EP1491627B1 (en) | Gene examination method for judging the onset risk of glaucoma | |
| US6083694A (en) | Method for elucidation and detection of polymorphisms, splice variants, and proximal coding mutations using intronic sequences of the alzheimer's S182 gene | |
| Morosini | Integrated genetic diagnosis of Neurofibromatosis type 1 (NF1) and molecular characterization of one case of compound heterozygosity | |
| US20060240461A1 (en) | Methods for detecting nemaline myopathy | |
| JP2001069984A (ja) | 第７番染色体片親性ダイソミーを検出する方法およびキット |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20190927 |